Prognostic Factors Affecting Survival of Gastric GIST

Clinicopathological Characteristics and Prognostic Factors of Gastrointestinal Stromal Tumors Located in the Stomach in Tunisian Patients

Gastrointestinal stromal tumor (GIST) is the most common non-epithelial mesenchymal tumor of the gastrointestinal tract. Surgical treatment is the only curative therapy for primary localized GIST. This study aimed to identify the clinicopathological characteristics of gastric GISTs and to study the predictive factors for recurrence in Tunisian patients.

Study Overview

• Status: Completed
• Conditions: Gastric GIST
• Intervention / Treatment: Other: total or subtotal gastrectomy

Detailed Description

The prognosis of gastric GIST depends on various tumor factors with the most important being the mitotic index and tumor necrosis. Imatinib therapy has revolutionized the treatment of advanced GIST.

They have been the subject of much controversy in terms of their histogenesis, classification, treatment and prognosis. GISTs are histologically similar to smooth muscle and nerve tumors such as leiomyomas, leiomyosarcomas or schwannomas. Currently they are well characterized with the recent discovery of the C-KIT gene mutation and the expression by tumor cells of the C-KIT protein.

Moreover, the discovery of this receptor is at the origin of the introduction of a "targeted therapy": an anti-tyrosine kinase molecule having revolutionized the therapeutic management of these tumors. However, the standard curative treatment of GIST remains complete surgical resection with negative margin from the tumor.

• Study Type: Observational
• Enrollment (Actual): 34

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 10 years to 90 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

There were 34 patients with the mean age of 58.2 years and male predominance. The disease was localized, locally advanced and metastatic in 26, 6 and 2 cases, respectively. Complete surgical resection was performed in 32 cases.

Description

Inclusion Criteria: patient having gastric GIST

-

Exclusion Criteria:

• patient operated for other gastric tumors

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Only
• Time Perspectives: Retrospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
prognostic factors of gastrointestinal stromal tumors; for the patient diagnosed with gastic GIST , they underwent subtotal or total gastrectomy.	Other: total or subtotal gastrectomy; resection of the gastric tumor

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
number of patients operated for gastric GIST	the patient having adenocarcinoma or other histopathological type are excluded	30 days

Collaborators and Investigators

• Sponsor: Université de Sousse
• Investigators: Study Director: ali ben ali, PROFESSOR, university of sousse

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2000
• Primary Completion (Actual): January 29, 2015
• Study Completion (Actual): January 2, 2018

Study Registration Dates

• First Submitted: February 12, 2020
• First Submitted That Met QC Criteria: February 12, 2020
• First Posted (Actual): February 17, 2020

Study Record Updates

• Last Update Posted (Actual): February 17, 2020
• Last Update Submitted That Met QC Criteria: February 12, 2020
• Last Verified: February 1, 2020

More Information

Terms related to this study

• Other Study ID Numbers: U23453

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No